He co-founded EnGeneIC and built it from concept to a clinical stage biopharmaceutical company (Sydney and New York). He is the principal inventor (435 granted patents world-wide) of EnGeneIC Dream Vector cyto-immunotherapeutic technology for treatment of several different cancers and for COVID-19. Himanshu is the principal author on several high impact scientific and clinical research papers. He has a strong background in R & D innovation and biopharmaceuticals business. He graduated with a Ph.D (University of Adelaide) and did post-doctoral research at the Geneva Medical Centre, National Centre for Research in Biotechnology (Germany) and CSIRO (Australia).
Keynote
Private Company
Healthcare, Biotech
Anthony Aho
PB&B
Anthony is a Swiss-Canadian bioengineer and co-inventor of PB&B’s technology. He obtained a BSc and MSc in Bioengineering & Biotechnology from EPFL. Prior to founding PB&B, he worked in cancer research and as a scientific collaborator in clinical research at CHUV.
Anthony is active in the startup communities in Europe and the US, mentoring and assessing new startups in various programs, and is an alumni member of StartX at Stanford and MassChallenge Boston.
Keynote
Private Company
Healthcare
Imprimatur Capital Fund Management
Keynote
Venture Capital
Healthcare, Ireland
Corporates
Company backgrounds and useful links.
EnGeneIC
Dr. Himanshu Brahmbhatt
EnGeneIC is a clinical-stage biopharmaceutical company, developing an innovative cyto-immunotherapy nanomedicine focused on cancer and COVID-19 treatments.
EDV (EnGeneIC Dream Vector) technology has the potential to save the lives of vulnerable (elderly and/or immune-compromised) coronavirus infected patients by lifting the suppressed immune system and producing the key virus fighting molecules in a physiological manner. This would prevent the virus from taking over both lungs, causing respiratory distress and subsequent death. Lifting of the virus fighting immune system has been demonstrated in end-stage cancer patients and EnGeneIC has manufactured the human doses to progress into a clinical trial in coronavirus infected patients.
Keynote
Private Company
Healthcare, Biotech
PB&B
Anthony Aho
PB&B is a specialty Swiss Life Sciences company founded by bioengineers working with plastic surgeons to test and bring to market a new patented injectable technology for the remodeling of soft tissues of the face and body.
As the face ages, fat loses volume causing facial sagging and wrinkles. Our injection superfeeds fat with lipids to reverse facial aging. Injected at large volume, breasts/buttocks can be enhanced naturally and without surgery.
PB&B is set to enter clinical testing to gain FDA approval and CE mark to enter the US and EU market in 2023.
